Clinical Rheumatology

, Volume 28, Issue 7, pp 841–845 | Cite as

Association of antiphosphatidylserine/prothrombin antibodies with neuropsychiatric systemic lupus erythematosus

  • Tomoko SyutoEmail author
  • Akira Shimizu
  • Yuko Takeuchi
  • Setsuko Tanaka
  • Michiko Hasegawa
  • Yayoi Nagai
  • Atsushi Tamura
  • Osamu Ishikawa
Brief Report


Neuropsychiatric manifestations in patients with systemic lupus erythematosus (SLE) are well-recognized symptoms although the pathophysiology of neuropsychiatric SLE (NPSLE) is unclear. Since an association with antiphospholipid antibodies has been reported, we examined the prevalence of antiphosphatidylserine–prothrombin antibodies (anti-PS/PT Abs), lupus anticoagulant (LA), anticardiolipin/β2-glycoprotein I antibodies (anti-β2-GPI Abs), and antiribosomal P protein antibodies (antiribosomal P Abs) in 68 SLE patients and analyzed their associations with neuropsychiatric manifestations. The prevalence of LA was significantly higher in the patients with neuropsychiatric (NP) features than those without NP features (P < 0.02). The levels of anti-PS/PT antibody were also significantly higher in the patients with NP features than those without NP features (P < 0.01). The results indicate that LA positivity and higher levels of anti-PS/PT antibody can be predictive markers for NPSLE.


Antiphosphatidylserine–prothrombin antibody Neuropsychiatric systemic lupus erythematosus 





  1. 1.
    Zandman-Goddard G, Chapman J, Shoenfeld Y (2007) Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum 36:297–315PubMedCrossRefGoogle Scholar
  2. 2.
    Sanna G, Bertolaccini M, Cuadrado M, Laing H, Khamashta M, Mathieu A et al (2003) Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 30:985–992PubMedGoogle Scholar
  3. 3.
    Avcin T, Benseler S, Tyrrell P, Cucnik S, Silverman E (2008) A followup study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus. Arthritis Rheum 59:206–213PubMedCrossRefGoogle Scholar
  4. 4.
    Tan EM, Cohen AS, Fries JF, Masi AT, Mcshane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRefGoogle Scholar
  5. 5.
    Karassa F, Afeltra A, Ambrozic A, Chang DM, Keyser FD, Doria A et al (2006) Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum 54:312–324PubMedCrossRefGoogle Scholar
  6. 6.
    Rheumatol (1999) The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42:599–608CrossRefGoogle Scholar
  7. 7.
    Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306PubMedCrossRefGoogle Scholar
  8. 8.
    Nojima J, Kuratsune H, Suehisa E, Kitani T, Iwatani Y, Kanakura Y (2004) Strong correlation between the prevalence of cerebral infarction and the presence of anti-cardiolipin/beta2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies—co-existence of these antibodies enhances ADP-induced platelet activation in vitro. Thromb Haemost 91:967–976PubMedGoogle Scholar
  9. 9.
    Nojima J, Iwatani Y, Suehisa E, Kuratsune H, Kanakura Y (2006) The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus. Haematologica 91:699–702PubMedGoogle Scholar
  10. 10.
    Nojima J, Masuda Y, Iwatani Y, Kuratsune H, Watanabe Y, Suehisa E et al (2008) Arteriosclerosis obliterans associated with anti-cardiolipin antibody/beta2-glycoprotein I antibodies as a strong risk factor for ischaemic heart disease in patients with systemic lupus erythematosus. Rheumatology (Oxford) 47:684–689CrossRefGoogle Scholar
  11. 11.
    Hasegawa M, Sato S, Yanaba K, Komura K, Yamazaki M, Takehara K (2004) Autoantibodies against phosphatidylserine-prothrombin complex in patients with systemic sclerosis. Ann Rheum Dis 63:1514–1517PubMedCrossRefGoogle Scholar
  12. 12.
    Hanly J, McCurdy G, Fougere L, Douglas J, Thompson K (2004) Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol 31:2156–2162PubMedGoogle Scholar
  13. 13.
    Sibbitt WJ, Brandt J, Johnson C, Maldonado M, Patel S, Ford C et al (2002) The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol 29:1536–1542PubMedGoogle Scholar
  14. 14.
    Hanly JG, Urowitz MB, Sanchez-Guerrero J, Bae SC, Gordon C, Wallace DJ et al (2007) Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum 56:265–273PubMedCrossRefGoogle Scholar
  15. 15.
    Khamashta M, Gil A, Anciones B, Lavilla P, Valencia M, Pintado V et al (1988) Chorea in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann Rheum Dis 47:681–683PubMedCrossRefGoogle Scholar
  16. 16.
    Ghosh J, Gupta D (2005) Chorea and microphonia as presenting feature of SLE. Indian J Pediatr 72:85CrossRefGoogle Scholar
  17. 17.
    Watanabe T, Onda H (2004) Hemichorea with antiphospholipid antibodies in a patient with lupus nephritis. Pediatr Nephrol 19:451–453PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2009

Authors and Affiliations

  • Tomoko Syuto
    • 1
    Email author
  • Akira Shimizu
    • 1
  • Yuko Takeuchi
    • 1
  • Setsuko Tanaka
    • 1
  • Michiko Hasegawa
    • 1
  • Yayoi Nagai
    • 1
  • Atsushi Tamura
    • 1
  • Osamu Ishikawa
    • 1
  1. 1.Department of DermatologyGunma University Graduate School of MedicineMaebashiJapan

Personalised recommendations